Get the Stockscreener App
5.96
0.17%
0.010
Pre-market:
6.02
0.06
+1.01%
Verastem Inc stock is traded at $5.96, with a volume of 1.07M.
It is up +0.17% in the last 24 hours and up +5.86% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$5.95
Open:
$6
24h Volume:
1.07M
Relative Volume:
0.57
Market Cap:
$523.54M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-1.7909
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+9.16%
1M Performance:
+5.86%
6M Performance:
-26.96%
1Y Performance:
-14.98%
1-Day Range:
$5.825
$6.08
1-Week Range:
$5.185
$6.08
52-Week Range:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.96 | 523.54M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
MSN Money - MSN
Earnings Preview: Verastem to Report Financial Results on May 07 - Moomoo
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem (VSTM) Launches Campaign for Recurrent Low-Grade Serous Ovarian Cancer - GuruFocus
KRAS-mutated LGSOC campaign debuts as Verastem, Inc. targets patient support - Traders Union
Verastem (VSTM) Projected to Post Earnings on Thursday - MarketBeat
Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating - marketscreener.com
CapEx per share of Verastem, Inc. – MUN:2VSA - TradingView
Verastem to Present at the 8th Annual JMP Securities Healthcare Conference - AOL.com
Liquidity Mapping Around (VSTM) Price Events - Stock Traders Daily
Verastem Oncology announces management changes - MSN
VSTM Price Today: Verastem, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VSTM Reiterated by BTIG -- Price Target Maintained at $19.00 - GuruFocus
Torray Investment Partners LLC Purchases Shares of 216,387 Verastem, Inc. $VSTM - MarketBeat
Verastem, Inc. sets first quarter earnings call for May 7 at 4:30pm ET - Traders Union
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 - ChartMill
VSTM Technical Analysis | Trend, Signals & Chart Patterns | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem Inc stock (US92335V1008): Is its oncology pipeline strong enough to unlock biotech upside? - AD HOC NEWS
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Verastem (NASDAQ:VSTM) Trading Down 4.1%Here's Why - MarketBeat
Verastem (VSTM) Stock Growth Drivers (Momentum Fading) 2026-04-20Retail Trader Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Vectoring In On Verastem (NASDAQ:VSTM) - Seeking Alpha
Verastem Inc stock (US92335V1008): Is its cancer therapy pipeline strong enough to unlock new upside - AD HOC NEWS
Verastem (VSTM) Stock: Cheap or Expensive (+3.79%) 2026-04-18Social Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai
Verastem (VSTM) Stock: Is It a Strong Buy? (Extends Gains) 2026-04-18Trend Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Verastem, Inc. (VSTM) Stock Analysis: 158% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
VSTM Stock Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Why (VSTM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Q4 2025 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - Eastern Progress
PI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, - openPR.com
Chipmakers Recap: How is Verastem Inc managing supply chain issues2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Verastem (NASDAQ:VSTM) Trading Up 7.6%What's Next? - MarketBeat
Aug Wrap: What analysts say about Verastem Inc stock2026 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com - Investing.com Canada
Is momentum building in Verastem (VSTM) Stock | Price at $5.63, Up 6.03%Trade Ideas - UBND thành phố Hải Phòng
Sentiment Recap: What analysts say about Verastem Inc stockTrade Entry Report & AI Optimized Trade Strategies - baoquankhu1.vn
Verastem Oncology’s combo shows two-year durability in ovarian cancer - MSN
Fed Meeting: What is the Moat Score of Verastem IncQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Today's Analyst Rating Data for VSTM: Maintained Buy Rating | VS - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 | VSTM Stock News - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 - GuruFocus
Verastem stock maintains Buy rating at BTIG on durable trial data - Investing.com Canada
Verastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG Research - MarketBeat
Verastem (VSTM) Presents Positive Two-Year Data for Ovarian Canc - GuruFocus
Verastem’s cancer drug combo shows durability in 2-year data By Investing.com - Investing.com India
Verastem’s cancer drug combo shows durability in 2-year data - Investing.com
Verastem Oncology announces two-year median follow-up data on Avmapki® Fakzynja® combination therapy - marketscreener.com
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):